Standard Lipid Panel Longevity-Medicine Target Ranges

What a Standard Lipid Panel Actually Measures

A standard lipid panel is a fasting blood test that reports five values: total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and non-HDL-C (TC minus HDL-C). Each value reflects a distinct aspect of cardiovascular risk, and none of them should be read in isolation.

Why the Panel Exists

The American Heart Association and American College of Cardiology have used lipid panels as the cornerstone of cardiovascular risk stratification for decades. Their 2019 Primary Prevention Guidelines recommend initiating a lipid panel in all adults aged 20 and older, repeated every four to six years for low-risk individuals [1]. The test costs roughly $10, $30 without insurance and requires a 9 to 12 hour fast for reliable triglyceride and Friedewald-estimated LDL-C accuracy.

LDL-C Is Calculated, Not Directly Measured

In most clinical labs, LDL-C is not directly measured. It is estimated using the Friedewald equation: LDL-C = TC minus HDL-C minus (TG divided by 5). This calculation becomes unreliable when triglycerides exceed 400 mg/dL. At that level, direct LDL-C measurement or the Martin-Hopkins equation should replace the standard estimate [2].

Non-HDL-C Captures More Risk Than LDL-C Alone

Non-HDL-C includes all atherogenic lipoproteins: LDL, VLDL, IDL, and Lp(a)-associated cholesterol. A 2019 meta-analysis in the Lancet pooling data from 38 cohorts (N=524,444) found non-HDL-C to be a stronger predictor of coronary heart disease mortality than LDL-C alone [3]. For longevity-focused care, non-HDL-C is therefore the preferred tracking metric alongside ApoB.

Conventional "Normal" Ranges Versus Longevity-Medicine Targets

Standard lab reference ranges flag values that exceed population averages in Western countries. Longevity medicine uses a different standard: the lowest levels consistent with no increased atherosclerotic risk, informed by Mendelian randomization studies of genetic LDL lowering from birth.

The Population-Average Problem

The conventional LDL-C upper limit of 100 mg/dL for primary prevention reflects median values in a population where cardiovascular disease is the leading cause of death. A 2020 Mendelian randomization study published in the Journal of the American College of Cardiology demonstrated that individuals with lifelong genetically low LDL-C (around 40 to 50 mg/dL) showed an 88% lower lifetime risk of major cardiovascular events compared to those with LDL-C around 130 mg/dL [4]. The benefit was proportional to duration of exposure, not just magnitude.

Longevity Targets by Marker

The table below contrasts conventional cutoffs with longevity-medicine targets used by preventive cardiologists and longevity-focused clinicians.

| Marker | Conventional "Normal" | Longevity-Medicine Target | |---|---|---| | LDL-C | <100 mg/dL (primary prevention) | <70 mg/dL; <55 mg/dL if high risk | | Non-HDL-C | <130 mg/dL | <80 mg/dL | | ApoB | <130 mg/dL | <80 mg/dL; <60 mg/dL if high risk | | Triglycerides | <150 mg/dL | <100 mg/dL | | HDL-C (men) | >40 mg/dL | >50 mg/dL | | HDL-C (women) | >50 mg/dL | >60 mg/dL | | Total Cholesterol | <200 mg/dL | Guided by LDL-C and ApoB |

Where the Targets Come From

The 55 mg/dL LDL-C threshold for very high-risk patients comes directly from the 2019 ESC/EAS Guidelines for the Management of Dyslipidemias, which states: "For patients at very high cardiovascular risk, an LDL-C goal of <1.4 mmol/L (<55 mg/dL) and a reduction of at least 50% from baseline are recommended." [5]. The 70 mg/dL target for moderate-to-high-risk primary prevention is supported by the JUPITER trial (N=17,802), in which rosuvastatin 20 mg reduced major cardiovascular events by 44% versus placebo, driving median LDL-C from 108 mg/dL to 55 mg/dL [6].

LDL-C: The Most Studied Atherogenic Marker

LDL-C remains the primary target of most lipid-lowering trials and guidelines. The causal relationship between LDL-C and atherosclerosis is supported by genetic, epidemiological, and interventional evidence spanning more than five decades.

Statin Trial Evidence

The Cholesterol Treatment Trialists' (CTT) Collaboration meta-analysis of 26 randomized trials (N=169,138) quantified that each 1 mmol/L (38.7 mg/dL) reduction in LDL-C reduced major vascular events by 22% (rate ratio 0.78, 95% CI 0.76 to 0.80, P<0.0001) [7]. Benefit was consistent across baseline LDL-C levels, age groups, and sexes.

Lower Is Better, With Caveats

FOURIER (N=27,564) tested evolocumab added to statin therapy. Median LDL-C fell from 92 mg/dL to 30 mg/dL. Major adverse cardiovascular events fell by 15% over a median 2.2 years (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) [8]. Critically, there was no lower safety threshold observed in FOURIER or ODYSSEY OUTCOMES (N=18,924), where alirocumab drove LDL-C to approximately 25 mg/dL without increased adverse events [9].

Practical LDL-C Targets for Longevity Patients

For a longevity-medicine patient without established ASCVD and no familial hypercholesterolemia, a pragmatic target is LDL-C below 70 mg/dL by age 40 to 50. If coronary artery calcium (CAC) scoring reveals a CAC score above 100, the target tightens to below 55 mg/dL. Statins remain the first-line pharmacological tool, but PCSK9 inhibitors and bempedoic acid offer additive options when statin intolerance or insufficient response occurs [10].

Triglycerides: Overlooked but Consequential

Triglycerides above 150 mg/dL are classified as borderline high by the 2018 AHA/ACC Guideline on the Management of Blood Cholesterol [10]. Longevity medicine sets the optimal threshold at below 100 mg/dL, based on epidemiological data showing that even values in the 100 to 149 mg/dL range associate with increased remnant cholesterol and insulin resistance.

Fasting Versus Non-Fasting Measurement

Non-fasting triglycerides are permissible for initial cardiovascular risk screening according to the 2016 European guidelines update [11]. A non-fasting value above 175 mg/dL triggers a fasting confirmation test. For longevity panel interpretation, fasting samples are preferred because postprandial variation can mask a metabolic trend.

Hypertriglyceridemia and Remnant Cholesterol

Elevated triglycerides raise remnant cholesterol (the cholesterol carried by VLDL and IDL particles). A Copenhagen Heart Study analysis (N=73,513) found that each 1 mmol/L increase in non-fasting remnant cholesterol corresponded to a 2.8-fold higher risk of ischemic heart disease independent of HDL-C [12]. Omega-3 fatty acid supplementation at prescription doses (icosapentaenoic acid, 4 g/day as Vascepa) reduced cardiovascular events by 25% in REDUCE-IT (N=8,179) among patients with triglycerides between 135 and 499 mg/dL already on statin therapy [13].

HDL-C: Higher Is Not Always Better

HDL-C above 60 mg/dL is classified as a "negative risk factor" in older ATP-III guidelines, suggesting it partially offsets cardiovascular risk. This is true up to a point.

The U-Shaped Risk Curve

A large observational study published in the European Heart Journal (N=116,508) found that HDL-C above 80 mg/dL in men was associated with higher all-cause mortality compared to HDL-C in the 40 to 60 mg/dL range [14]. The same pattern appeared at HDL-C above 100 mg/dL in women. The working hypothesis is that extremely high HDL-C reflects dysfunctional particles with impaired cholesterol efflux capacity, though causality has not been established.

Why HDL-Raising Drugs Have Largely Failed

Multiple pharmacological HDL-C-raising agents, including niacin and the CETP inhibitors torcetrapib, dalcetrapib, and evacetrapib, failed to reduce cardiovascular events in large trials despite raising HDL-C by 20 to 130% [15]. Anacetrapib (REVEAL trial, N=30,449) did produce a modest 9% reduction in major coronary events, but the FDA did not approve it [16]. Functional HDL testing, including cholesterol efflux capacity assays, may be a better longevity marker than HDL-C mass alone.

Practical HDL-C Interpretation

Target HDL-C above 50 mg/dL for men and above 60 mg/dL for women, using lifestyle measures: aerobic exercise (150 minutes per week of moderate intensity raises HDL-C by approximately 3 to 6 mg/dL [17]), alcohol reduction, smoking cessation, and replacing refined carbohydrates with unsaturated fats. Do not attempt to raise HDL-C above 80 mg/dL pharmacologically.

Non-HDL-C and ApoB: The Longevity Tier-One Metrics

Non-HDL-C and ApoB better capture atherogenic particle burden than LDL-C alone. Each LDL, VLDL, IDL, chylomicron remnant, and Lp(a) particle carries exactly one ApoB molecule, making ApoB a direct particle-count proxy.

ApoB Superior to LDL-C for Risk Prediction

A 2021 analysis from the ARIC study (N=15,792) showed that ApoB was more strongly associated with incident coronary heart disease than LDL-C after adjusting for metabolic variables (HR 1.46 per SD increase in ApoB vs. HR 1.25 per SD increase in LDL-C) [18]. ApoB is particularly informative in patients with metabolic syndrome, where LDL-C is often falsely reassuring because particle count is elevated while cholesterol content per particle is low.

Longevity-Medicine ApoB Consensus

A practical HealthRX framework for ApoB target-setting by risk tier:

• Tier 1 (no risk factors, CAC = 0, age <45): ApoB below 90 mg/dL
• Tier 2 (1 to 2 risk factors or CAC 1 to 99, age 45 to 65): ApoB below 80 mg/dL
• Tier 3 (established ASCVD, CAC >100, diabetes, or familial hypercholesterolemia): ApoB below 60 mg/dL

These thresholds align with the 2022 European Atherosclerosis Society Consensus Statement on ApoB, which recommends ApoB below 65 mg/dL for very high-risk patients [19].

How to Use ApoB When the Standard Panel Is Ordered

ApoB is not a standard lipid panel component in most labs, but it can be ordered as an add-on for approximately $15, $30. When ApoB is unavailable, non-HDL-C serves as the next-best surrogate. The correlation between non-HDL-C and ApoB is approximately 0.87, though discordance increases at higher triglyceride levels [20].

Total Cholesterol: Still Useful, Still Misread

Total cholesterol above 200 mg/dL triggers a "borderline high" flag in most lab reports. Total cholesterol alone is a poor risk predictor. A total cholesterol of 220 mg/dL driven by HDL-C of 90 mg/dL carries a very different risk profile than 220 mg/dL with HDL-C of 30 mg/dL and LDL-C of 160 mg/dL.

When Total Cholesterol Matters

Total cholesterol is relevant in two scenarios: first, as an input into cardiovascular risk calculators like the Pooled Cohort Equations (PCE) used in ACC/AHA guidelines; second, as a screening test in non-fasting settings where LDL-C cannot be estimated [1]. For any patient in a longevity program, total cholesterol should always be interpreted in context of the full panel plus ApoB.

Treating to a Total Cholesterol Number Is Outdated

The 2018 AHA/ACC guideline explicitly moved away from treating to total cholesterol targets, shifting the focus to LDL-C reduction percentage from baseline and absolute thresholds for high-risk groups [10]. Longevity medicine takes this further by centering treatment decisions on ApoB and non-HDL-C rather than total cholesterol.

How Longevity Clinicians Use the Panel in Practice

A standard lipid panel is typically the entry point, not the destination, in a longevity workup. Clinicians layer additional tests based on initial results.

Baseline Panel at Age 20 to 30

Every adult should have a baseline fasting lipid panel between age 20 and 30. This establishes familial hypercholesterolemia screening (LDL-C above 190 mg/dL at a young age is diagnostic until proven otherwise) and captures a lifetime reference point. The USPSTF recommends screening men starting at age 35 and women at age 45 for dyslipidemia, but many longevity clinicians begin at 20 [21].

Sequential Add-Ons After Initial Results

If LDL-C exceeds 100 mg/dL or non-HDL-C exceeds 130 mg/dL on a baseline panel, the standard HealthRX protocol adds:

1. ApoB (particle count proxy)
2. Lp(a) (genetically fixed; one lifetime measurement suffices)
3. Fasting insulin and glucose (to assess insulin resistance driving triglycerides)
4. HsCRP (inflammatory component of residual risk)
5. CAC score if age is 40 or older (hard imaging endpoint)

Retesting Frequency

While titrating statin or PCSK9 inhibitor therapy, recheck the panel at 6 to 8 weeks after dose change, then every 3 to 6 months until targets are stable. Once stable below target, annual retesting is appropriate [10]. Patients on high-intensity statins should also have periodic CK and hepatic function panels, though routine monitoring is not mandated by guidelines if the patient is asymptomatic.

Lifestyle Interventions With Quantified Lipid Effects

Pharmacology is not the only path to longevity lipid targets. Diet and exercise produce meaningful shifts, especially in triglycerides and HDL-C.

Dietary Changes

Replacing saturated fats with polyunsaturated fats reduces LDL-C by approximately 10 to 15 mg/dL [22]. A Mediterranean-style dietary pattern, tested in PREDIMED (N=7,447), did not significantly reduce total LDL-C but reduced LDL oxidation, Lp(a), and cardiovascular events by 30% compared to a low-fat control diet [23]. Reducing refined carbohydrates and added sugar is the most effective dietary intervention for lowering triglycerides, capable of reducing fasting TG by 30 to 50% in hypertriglyceridemic individuals.

Exercise

Aerobic exercise raises HDL-C by 3 to 6 mg/dL at 150 minutes per week of moderate intensity [17]. Resistance training adds modest LDL-C reduction of approximately 3 to 5 mg/dL. Neither replaces pharmacotherapy in patients with LDL-C above 130 mg/dL who are aiming for longevity targets of below 70 mg/dL.

Sleep and Stress

Poor sleep (below 6 hours per night) associates with higher triglycerides and lower HDL-C in cross-sectional data from the National Health and Nutrition Examination Survey [24]. Chronic psychological stress raises cortisol, which in turn increases hepatic VLDL production and triglycerides. These are modifiable inputs that belong in the longevity lipid conversation even though they rarely appear in standard clinical notes.